News from #ASH25 Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

Mon T W Th F 8 December, 2025

See What’s Ahead—Download the 2026 Market Access Trends Report sponsored by Cencora

presented by Pra­tia ac­cel­er­ates U.S. ex­pan­sion with ma­jor­i­ty in­vest­ment in P1 Tri­als, strength­en­ing its glob­al ear­ly-phase on­col­o­gy net­work

news Kymera's Dupixent-in-a-pill impresses in closely-watched early eczema readout Wave Life Sciences says its RNA obesity shot cuts fat but retains muscle Kallyope heads to Phase 3 with migraine drug after mid-stage success Apple Tree Partners scores legal win against alleged holdout Russian investor ORIC’s lung cancer pill shows promise in some settings but is dropped for HER2 mutations

News from #ASH25 As one door closes for Regeneron’s lymphoma bispecific, another reopens AstraZeneca's dual-targeting CAR-T sees similar response rates in Western patients as in China Star Therapeutics details early data for blood disorder shot, weighs IPO potential

Dec 09 11:00am ET Strategic solutions for cost, time and quality challenges in drug development sponsored by Cambrex Dec 16 11:30am ET Ensure EU GMP Annex I compliance while maintaining sterile injectable manufacturing excellence & agility sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

Our latest survey captured the bleakest biotech outlook in a decade — but is recent momentum real or a mirage? Join us to hear what CEOs are saying about the industry’s direction. Sign up now.

endpoints pharma Pinpointing the moment when biopharma sentiment finally turned NICE adds further details on how the UK will pay more for drugs ‘This is unconscionable’: ACIP no longer recommends hepatitis B birth dose for all children Bristol Myers expands Breyanzi approval to marginal zone lymphoma

in case you missed it 1. With backing from Pfizer and others, China startup raises $100M in new twist on licensing model 2. Peer Review Ex-Intercept CEO takes over at Altimmune; Carolyn Bertozzi leaves Alnylam's board 3. Praxis stops pivotal trial of rare epilepsy drug early for efficacy 4.